未来展望脓毒症和感染性休克的诊治。
Future Perspectives in the Diagnosis and Treatment of Sepsis and Septic Shock.
机构信息
Second Department of Critical Care, Attikon General University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
First Department of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, Medical School, National and Kapodistrian University of Athens, 10676 Athens, Greece.
出版信息
Medicina (Kaunas). 2022 Jun 24;58(7):844. doi: 10.3390/medicina58070844.
Abstract
Sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, represents the primary cause of death due to infection [...].
摘要
败血症，定义为感染引起的宿主反应失调导致的危及生命的器官功能障碍，是感染相关死亡的主要原因[... ]。
相似文献
1
Future Perspectives in the Diagnosis and Treatment of Sepsis and Septic Shock.未来展望脓毒症和感染性休克的诊治。
Medicina (Kaunas). 2022 Jun 24;58(7):844. doi: 10.3390/medicina58070844.
2
Updates and controversies in the early management of sepsis and septic shock.脓毒症和感染性休克早期处理的更新与争议。
Emerg Med Pract. 2021 Apr 15;23(Suppl 4-2):1-24.
3
Points & Pearls: Updates and controversies in the early management of sepsis and septic shock.要点与精华：脓毒症及脓毒性休克早期管理的更新与争议
Emerg Med Pract. 2018 Oct 1;20(Suppl 10):1-2.
4
Sepsis and Septic Shock - Basics of diagnosis, pathophysiology and clinical decision making.脓毒症与脓毒性休克 - 诊断基础、病理生理学与临床决策。
Med Clin North Am. 2020 Jul;104(4):573-585. doi: 10.1016/j.mcna.2020.02.011. Epub 2020 May 12.
5
[Sepsis : particularities in the elderly patients].[脓毒症：老年患者的特殊性]
Rev Med Suisse. 2016 Nov 9;12(538):1917-1921.
6
[New Sepsis-3 definition : Do we have to treat sepsis before we can diagnose it from now on?].[新的脓毒症-3定义：从现在起，我们必须在诊断脓毒症之前就进行治疗吗？]
Anaesthesist. 2017 Aug;66(8):614-621. doi: 10.1007/s00101-017-0316-2.
7
Updates and controversies in the early management of sepsis and septic shock.脓毒症和脓毒性休克早期管理的进展与争议
Emerg Med Pract. 2018 Oct;20(10):1-28. Epub 2018 Oct 1.
8
Sepsis and septic shock: current approaches to management.脓毒症和感染性休克：当前的治疗方法。
Intern Med J. 2019 Feb;49(2):160-170. doi: 10.1111/imj.14199.
9
Management of Sepsis and Septic Shock for the Obstetrician-Gynecologist.妇产科医生对脓毒症和脓毒性休克的管理
Obstet Gynecol Clin North Am. 2016 Dec;43(4):659-678. doi: 10.1016/j.ogc.2016.07.010.
10
Early identification and management of patients with severe sepsis and septic shock in the emergency department.急诊科对严重脓毒症和脓毒性休克患者的早期识别与处理
Emerg Med Clin North Am. 2014 Nov;32(4):759-76. doi: 10.1016/j.emc.2014.07.002. Epub 2014 Sep 3.
引用本文的文献
1
Analysis of the association between cholinesterase and in-hospital mortality in children with bloodstream infections in the pediatric intensive care unit.儿科重症监护病房血流感染患儿胆碱酯酶与院内死亡率的相关性分析
Front Pediatr. 2025 Aug 8;13:1588634. doi: 10.3389/fped.2025.1588634. eCollection 2025.
2
Partial depletion of circulating neutrophil granulocytes in mice exacerbates the inflammatory response and hypothermia during LPS induced severe systemic inflammation.小鼠循环中性粒细胞部分耗竭会加剧脂多糖诱导的严重全身炎症期间的炎症反应和体温过低。
Front Immunol. 2025 Jun 4;16:1578590. doi: 10.3389/fimmu.2025.1578590. eCollection 2025.
3
Kinetics of the Lactate to Albumin Ratio in New Onset Sepsis: Prognostic Implications.新发脓毒症中乳酸与白蛋白比值的动力学：预后意义
Diagnostics (Basel). 2024 Sep 8;14(17):1988. doi: 10.3390/diagnostics14171988.
4
Applications of peptides in nanosystems for diagnosing and managing bacterial sepsis.肽在用于诊断和治疗细菌性败血症的纳米系统中的应用。
J Biomed Sci. 2024 Apr 19;31(1):40. doi: 10.1186/s12929-024-01029-2.
5
Research Progress of DcR3 in the Diagnosis and Treatment of Sepsis.DcR3 在脓毒症诊治中研究进展。
Int J Mol Sci. 2023 Aug 18;24(16):12916. doi: 10.3390/ijms241612916.
6
Diagnostic and Prognostic Performance of Plasma Albumin and Cholinesterase in Patients with Sepsis and Septic Shock.血浆白蛋白和胆碱酯酶对脓毒症和感染性休克患者的诊断和预后价值。
Med Princ Pract. 2023;32(2):133-142. doi: 10.1159/000530631. Epub 2023 Apr 17.
7
Perspectives in vaccines, immune response, therapeutic interventions and COVID-19.疫苗、免疫反应、治疗干预措施与新型冠状病毒肺炎的相关观点
Metabol Open. 2023 Mar;17:100223. doi: 10.1016/j.metop.2022.100223. Epub 2022 Dec 17.
本文引用的文献
1
Changes in immune function and immunomodulatory treatments of septic patients.脓毒症患者免疫功能的变化和免疫调节治疗。
Clin Immunol. 2022 Jun;239:109040. doi: 10.1016/j.clim.2022.109040. Epub 2022 May 13.
2
Hemoperfusion: technical aspects and state of the art.血液灌流：技术层面与最新进展。
Crit Care. 2022 May 12;26(1):135. doi: 10.1186/s13054-022-04009-w.
3
Precision medicine in sepsis and septic shock: From omics to clinical tools.脓毒症和脓毒性休克中的精准医学：从组学到临床工具。
World J Crit Care Med. 2022 Jan 9;11(1):1-21. doi: 10.5492/wjccm.v11.i1.1.
4
Vasopressor Choice and Timing in Vasodilatory Shock.血管扩张性休克中血管活性药物的选择与时机
Crit Care. 2022 Mar 22;26(1):76. doi: 10.1186/s13054-022-03911-7.
5
Circulating Chemerin and Its Kinetics May Be a Useful Diagnostic and Prognostic Biomarker in Critically Ill Patients with Sepsis: A Prospective Study.循环趋化素及其动力学可能是脓毒症危重症患者有用的诊断和预后生物标志物：一项前瞻性研究。
Biomolecules. 2022 Feb 12;12(2):301. doi: 10.3390/biom12020301.
6
A guide to immunotherapy for COVID-19.针对 COVID-19 的免疫疗法指南。
Nat Med. 2022 Jan;28(1):39-50. doi: 10.1038/s41591-021-01643-9. Epub 2022 Jan 21.
7
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.拯救脓毒症运动：2021年脓毒症和脓毒性休克国际管理指南
Intensive Care Med. 2021 Nov;47(11):1181-1247. doi: 10.1007/s00134-021-06506-y. Epub 2021 Oct 2.
8
Blood purification in sepsis and systemic inflammation.脓毒症和全身炎症中的血液净化。
Curr Opin Crit Care. 2021 Dec 1;27(6):582-586. doi: 10.1097/MCC.0000000000000890.
9
Circulating leptin, soluble leptin receptor and free leptin index in critically ill patients with sepsis: a prospective observational study.脓毒症重症患者的循环瘦素、可溶性瘦素受体及游离瘦素指数：一项前瞻性观察研究。
Minerva Anestesiol. 2021 Aug;87(8):880-890. doi: 10.23736/S0375-9393.21.15368-4. Epub 2021 Jun 8.
10
Serum bilirubin to fetuin-A ratio as a prognostic biomarker in critically ill patients with sepsis.血清胆红素与胎球蛋白-A比值作为脓毒症重症患者的预后生物标志物
Metabol Open. 2021 May 1;10:100094. doi: 10.1016/j.metop.2021.100094. eCollection 2021 Jun.
Zotero 插件